Duration and Timing of Initiation of Therapy With Platelet P2Y12 Inhibitors in the Treatment of Patients With Acute Coronary Syndrome

In recent years, the issues of choice of an agent for dual antiplatelet therapy (DAPT) as well as timing of initiation and duration of DAPT in patients with acute coronary syndrome (ACS) have been actively discussed. In this article we present data of major randomized trials of clopidogrel and novel...

Full description

Saved in:
Bibliographic Details
Published inKardiologiia no. 3; p. 54
Main Authors SHalaev, S V, Safiullina, Z M
Format Journal Article
LanguageEnglish
Russian
Published Russia (Federation) 01.03.2018
Subjects
clopidogrel
dual antiplatelet therapy
P2Y12 inhibitors
prasugrel
acute coronary syndrome
cangrelor
ticagrelor
Online AccessGet more information

Cover

More Information
Summary:In recent years, the issues of choice of an agent for dual antiplatelet therapy (DAPT) as well as timing of initiation and duration of DAPT in patients with acute coronary syndrome (ACS) have been actively discussed. In this article we present data of major randomized trials of clopidogrel and novel P2Y12 inhibitors - prasugrel, ticagrelor, cangrelor - assessing strategy of administration of antiaggregants in patients with ACS before coronary angiography / percutaneous coronary intervention. The article also contains analysis of differences between recommendations of the European Society of Cardiology and American College of Cardiology/American Heart Association on therapy with oral P2Y12 inhibitors in the management of patients with ACS.
ISSN:0022-9040
DOI:10.18087/cardio.2018.3.10099